Your browser doesn't support javascript.
loading
Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines.
Bowen, John E; Sprouse, Kaitlin R; Walls, Alexandra C; Mazzitelli, Ignacio G; Logue, Jennifer K; Franko, Nicholas M; Ahmed, Kumail; Shariq, Asefa; Cameroni, Elisabetta; Gori, Andrea; Bandera, Alessandra; Posavad, Christine M; Dan, Jennifer M; Zhang, Zeli; Weiskopf, Daniela; Sette, Alessandro; Crotty, Shane; Iqbal, Najeeha Talat; Corti, Davide; Geffner, Jorge; Grifantini, Renata; Chu, Helen Y; Veesler, David.
Afiliación
  • Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Sprouse KR; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Walls AC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
  • Mazzitelli IG; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA.
  • Logue JK; Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Buenos Aires C1121ABG, Argentina.
  • Franko NM; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA.
  • Ahmed K; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA.
  • Shariq A; Department of Paediatrics and Child Health, and Biological & Biomedical Sciences, Aga Khan University, Karachi 74800, Pakistan.
  • Cameroni E; Department of Paediatrics and Child Health, and Biological & Biomedical Sciences, Aga Khan University, Karachi 74800, Pakistan.
  • Gori A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
  • Bandera A; Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Posavad CM; Department of Pathophysiology and Transplantation,, University of Milan, Milan, Italy.
  • Dan JM; Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy.
  • Zhang Z; Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Weiskopf D; Department of Pathophysiology and Transplantation,, University of Milan, Milan, Italy.
  • Sette A; Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy.
  • Crotty S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Iqbal NT; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
  • Corti D; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA UC92037, USA.
  • Geffner J; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
  • Grifantini R; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
  • Chu HY; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
  • Veesler D; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA UC92037, USA.
bioRxiv ; 2022 Mar 16.
Article en En | MEDLINE | ID: mdl-35313570
The SARS-CoV-2 Omicron variant of concern comprises three sublineages designated BA.1, BA.2, and BA.3, with BA.2 steadily replacing the globally dominant BA.1. We show that the large number of BA.1 and BA.2 spike mutations severely dampen plasma neutralizing activity elicited by infection or seven clinical vaccines, with cross-neutralization of BA.2 being consistently more potent than that of BA.1, independent of the vaccine platform and number of doses. Although mRNA vaccines induced the greatest magnitude of Omicron BA.1 and BA.2 plasma neutralizing activity, administration of a booster based on the Wuhan-Hu-1 spike sequence markedly increased neutralizing antibody titers and breadth against BA.1 and BA.2 across all vaccines evaluated. Our data suggest that although BA.1 and BA.2 evade polyclonal neutralizing antibody responses, current vaccine boosting regimens may provide sufficient protection against Omicron-induced disease.
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: BioRxiv Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: BioRxiv Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos